SPONSORED

UK CBD market to reach 1.2bn this year

The United Kingdom has one of the most favourable CBD legislations in the world.

•• 3 Min
UK CBD market to reach 1.2bn this year

Due to increased demand during curfew and the relaxation of regulations, the UK CBD market is set to reach record sales of £ 690 million ($ 1.2 billion) this year. That came from a new report released this week by two cannabis industry groups that concluded that "Britain now has the most advanced regulatory framework in the world for CBD." The paper, Green Shoots: Sowing The Seeds Of The New UK Cannabis Industry, was written by the Association for the Cannabinoid Industry and the Center for Medicinal Cannabis. Industry groups say the government's new support has sparked a "silent cannabis revolution" in the UK as CBD stores continue to pop up in the island nation's cities. The newspaper cites how the UK became the first country in the European Union in 2018 to create a legal framework for cannabis-based medicinal products, opening up prescriptions and medical research opportunities with patients. Cannabidiol, or CBD, is the non-psychoactive compound extracted from both cannabis and hemp plants. Over the past year, the extract has been used in myriad products marketed to treat conditions such as anxiety, insomnia, and acne. However, CBD research is still in the process of proving these health claims. This year the U.K. Foods Standards Agency opened up the domestic CBD industry by regulating the products as dietary supplements. Independently of this, the Ministry of the Interior - the federal agency responsible for immigration, security and law and order - is working on establishing rules for safe and tolerable THC levels in health products. These policy advances have led industry groups to raise their forecast for the size of the UK CBD market in 2021 by a third from an earlier estimate of £ 526 million ($ 888 million). "The size of this cannabinoid sector is impossible to ignore right now," CMC and ACI co-founder and study co-author Paul Birch said in a statement. "Almost unnoticed and certainly more by accident than planned, the UK has become the second largest cannabinoid consumer market in the world." However, the report claims that more government intervention and investment is needed to develop domestic CBD and hemp production opportunities. With the UK restricting hemp cultivation and processing of cannabidiol, the authors note that the major profits of the industry go overseas. Under current legislation, hemp farmers are forced to destroy up to 80 percent of their crops, including the plant's precious, CBD-rich flowers. The industry groups argue that the market is an important growth sector for the UK to stimulate post-turnaround economic growth. Your paper calls on the government to adopt a "proactive strategy" to support job creation and the growth of the cannabinoid sector. The report includes 20 recommendations that the industry groups recently presented to the new government task force on innovation, growth and regulatory reform set up by UK Prime Minister Boris Johnson in February. These recommendations include: a new center of excellence to fund and promote the best new clinical knowledge to fuel the emerging medical cannabis market in the UK; and an urgent regulatory reform to steer and leverage emerging scientific knowledge across the spectrum: from agricultural science and plant genetics to novel synthetics, new therapies and clinical trials.

CBDCannabisGreat Britain

Most Popular News

  1. SpaceX’s $8B Spectrum Deal Sends AT&T, Verizon, and T-Mobile Plummeting
  2. Is Project Vault Securing America’s Supply Chain or Squeezing It to the Breaking Point?
  3. Why Gautam Lohia Shifted from Global Consulting to Reboot a $20M Tech Micro-Cap
  4. Everyday Luxury, Unstoppable Scale: Aritzia Delivers 44% Net Revenue Growth
  5. Can Navy SEAL Leadership and Big Tech Scale Revolutionize Airborne Threat Detection?

Disclaimer


This report should not be viewed as investment advice or as an offer to buy or sell any securities or as an invitation or solicitation of an offer to buy or sell any securities. Neither the author of this report, its publisher, nor any other person associated with the publication of this report, are registered brokers, investment dealers, investment advisers, or financial advisers. The information in this report has not been tailored to the particular needs or circumstances of readers and should not be relied upon as investment advice or recommendations to purchase or sell any of the securities presented in this report. Readers seeking investment advice should contact qualified and registered brokers, investment dealers, investment advisers, or financial advisers prior to making any decision to buy or sell any of the securities referred to in this report. The information in this report should not be construed as investment, legal, or tax advice. No recommendation is made as to whether an investment in the presented securities is suitable for any reader in light of the reader’s particular circumstances.

Readers are cautioned that the publisher of this report covers exclusively securities that carry a high degree of volatility. Investing in such securities is highly speculative and carries a high degree of risk. Investors in such securities could lose all or a substantial portion of their investment. Only those investors who can afford to lose all or a substantial portion of their investment should consider investing in the securities referred to in this report.

This report may include information obtained from publicly available sources, including third-party reports or analysis. Neither the author nor publisher of this report, nor www.juniorstocks.com or its owners, have undertaken any independent investigation into the factual information used in this report, and the information in this report is provided without any warranty of any kind. No representations or warranties are provided regarding the accuracy or completeness of the information provided in this report. Statements of opinion or belief are those of the authors and/or publisher of this report. These statements of opinion or belief are expressions of the author’s and/or publisher’s judgment, and there is no guarantee that those judgments will turn out to be correct. No inference should be drawn that the author and/or publisher have any special or greater knowledge about the presented companies or their securities, or any particular expertise in the industries or markets in which the company operates. Readers should conduct their own due diligence and seek professional advice prior to investing in any securities presented on Juniorstocks.com.

Certain statements in this report constitute “forward-looking” statements. Forward-looking statements often, but not always, are identified by the use of words such as “seek,” “anticipate,” “believe,” “plan,” “estimate,” “expect,” “targeting,” and “intend” and statements that an event or result “may,” “will,” “should,” “could,” or “might” occur or be achieved and other similar expressions. Forward-looking statements express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance; they are not statements of historical facts and should not be viewed as any guarantee of any future result. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. The author and/or publisher of this report disclaims any obligation to update the forward-looking statements in this report, whether as a result of new information, future events, or results or otherwise. There is no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to applicable law or regulation, or would subject the author or publisher of this report to any registration requirement in such jurisdiction or country.

Information about the editor of this publication:
Juniorstocks.com is a service provided by Piccadilly Capital Group, Office 66, 101 Clapham High Street, London, SW4 7TB, UK. Piccadilly Capital Group is not the publisher of this report and was not paid for the publication of this report. Piccadilly Capital Group seeks to generate web traffic and a growing number of followers through the publication of articles or reports. Directors, officers, and other insiders of the publisher own an interest in Piccadilly Capital Group. Piccadilly Capital Group does not endorse or recommend the business, products, services, or securities of any company mentioned on www.juniorstocks.com. Piccadilly Capital Group will not share your information with any outside third parties. Due to the new data protection basic regulation, we ask you to read our data protection declaration carefully.

Note on copyright:
The contents published on this website and on connected media (e.g., e-mail, X, Facebook) are subject to applicable copyright and ancillary copyright laws. Any use not permitted by applicable copyright and ancillary copyright laws requires the prior written consent of the provider or the respective rights holder. In particular, this applies to the duplication, editing, translation, storage, processing, or reproduction of content in databases or other electronic media and systems. Contents and rights of third parties are marked as such. Unauthorized reproduction or transmission of individual contents or complete pages is not permitted and is punishable by law. Only the production of copies and downloads for personal, private, and non-commercial use is permitted. Links to the provider's website are always welcome and do not require the consent of the provider of the website. Photos and images on the website may not be shared unless the publisher itself has acquired the initial rights from authorized sources. The presentation of this website in external frames is only allowed with written permission. If you notice any violations, please inform us. Please note: The content of our articles, emails, or other publications or social networks such as X, LinkedIn or Facebook is exclusively intended for the designated addressee(s). If you are not the addressee of these articles, emails, or other publications in the market letter or social networks such as Twitter or Facebook or his or her legal representative, please note that any form of publication, reproduction, or distribution of the content of these articles, emails, or other publications in the market letter or social networks such as X, LinkedIn or Facebook is prohibited. Falsifications of the original content of this message during data transmission cannot be excluded in principle.